fda warning letters compounded semaglutide 2025 U.S. sends drug advertising to Lilly, Novo, Hims FDA Warning Letter Breakdown: Sterility
Description
Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

Despite their current dominance, GLP-1R agonists are not the only contributors to future growth

Treatment matched to your body and goals Same dose for everyone

Its the missing layer that turns GLP-1 treatment from a one-size-fits-all pathway into a true precision-health experience
Once you begin Semaglutide treatment, we provide ongoing monitoring and support to ensure that the treatment is effective and well-tolerated

Be thorough on the health questionnaire
